Company News & Press

18 February 2021

Metabolon Collaborates with Cleveland Clinic to Enable Novel Discoveries

Metabolon, Inc. has entered into a multi-year collaborative agreement with Cleveland Clinic to provide Metabolon’s Precision Metabolomics™ services in support of drug development and related research efforts. Metabolon will leverage its proprietary platform to analyze a range of biologic samples to help discover metabolomic biomarkers that will deepen understanding of Cleveland Clinic’s novel discoveries, improve speed of decision-making and accelerate clinical trials.

23 November 2020

National Institute of Allergy and Infectious Disease (NIAID) Selects Metabolon, Inc. for COVID-19 Study

“We are honored to partner with NIAID and Metabolon in this effort to define how the human response to SARS-CoV-2 correlates to COVID severity and outcome. Metabolic features of the immune responses are increasingly recognized as pivotal to disease and health, and we are fortunate to have Metabolon’s excellent team by our side as we undertake this critical work.” – Dr. Ofer Levy, Director of the Precision Vaccines Program (PVP) at Boston Children’s Hospital

23 September 2020

Metabolon, Inc. Announces $72 Million in Debt and Equity Financing to Accelerate Advancements in Precision Medicine and Innovative Drug Development Technologies

New and existing investors contributed to biotech’s largest ever capital raise; company also announced appointment of Robert A. Cascella, Chief Business Leader, Precision Diagnostics, and Executive Vice President of Phillips, as one of three independent members of the Metabolon Board of Directors.

6 August 2020

Metabolon, Inc. Joins SOPHIA, International Research Consortium

Metabolon will perform metabolomics on study participants as part of the five-year longitudinal study to improve risk assessment of complications of obesity, supporting greater understanding in patient stratification for the right treatment depending on metabolic profiles.

3 August 2020

Metabolon Announces Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany

Metabolomic insights will support the leading science and technology company in advancement of its drug early development programs across therapeutic areas.

22 June 2020

Metabolon, Inc. and DNA Genotek Collaborate on First Ambient-Temperature Microbiome Sampling Solution for Metabolomics

OMNImet™·GUT expands access to critical metabolomic analysis with development of in-home fecal collection device – the first device for in-home collection and ambient-temperature storage and shipping of fecal samples for metabolomics, to the research market.

20 June 2020

Enlightening a Company, By Design

Metabolon, Inc. has unveiled a new brand rooted in its 20-year history as a revolutionary leader in metabolomics. The company's corporate mission to "enlighten life and enable a better, healthier world," reflects the unique value and urgency of Precision Metabolomics™ in expanding and accelerating discovery across life sciences research.

20 May 2020

Metabolon Wins Five Year Contract with U.S. Army Research Institute of Environmental Medicine

Metabolomic insights will support Army’s research into Warfighter health-readiness and optimal performance. Metabolon, Inc., the global leader in metabolomics, has been selected by the U.S. Army Research Institute of Environmental Medicine (USARIEM), to analyze the metabolic profiles of military personnel in a research program being conducted by the Military Nutrition Division.

4 October 2019

Metabolon, Inc. Appoints Karl Bradshaw, Ph.D., to Lead Biopharma Strategy and Partnering

“We welcome Karl at an exciting time when Metabolon is implementing new strategies to increase our growth and prominence as the biotech partner capable of addressing the most difficult questions in the life sciences through our unmatched approach to metabolomics,” said Rohan Hastie, Ph.D., President and CEO, Metabolon.

10 July 2019

New partnership leveraging metabolomics to uncover reasons for frailty in aging populations

Metabolon, Inc. joins forces with three Canadian research groups – The Canadian Frailty Network, the Canadian Longitudinal Study of Aging (CLSA) and the McMaster Institute for Research on Aging (MIRA) – to discover the frailty biomarkers that may shed light on why some people become frail, determine the severity of frailty and what can be done to help avoid the condition.

Find Us at These Events

Watch On-Demand Webinars